^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
adecatumumab (MT201)
i
Other names: MT201, MT 201, Human anti-EpCAM monoclonal antibody MT201
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen
Drug class:
EPCAM inhibitor
Related drugs:
over2years
DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
P1, N=27, Not yet recruiting, Michael Gunn | Trial completion date: Dec 2022 --> Mar 2024 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Trial completion date • Trial initiation date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
|
temozolomide • MT-201 • adecatumumab (MT201)
over2years
DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
P1, N=27, Not yet recruiting, Michael Gunn | Initiation date: Sep 2021 --> Dec 2021
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
|
temozolomide • MT-201 • adecatumumab (MT201)
over3years
DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
P1, N=27, Not yet recruiting, Michael Gunn
New P1 trial
|
MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
|
temozolomide • adecatumumab (MT201)
almost4years
[VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO-I 2020)
All subjects received Sandostatin® (100μg immediate release; SIR) by deep SC injection 24h before MTD201... MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
Clinical • PK/PD data • Late-breaking abstract
|
IGF1 (Insulin-like growth factor 1)
|
Octreosphere (octreotide extended release) • adecatumumab (MT201) • octreotide acetate • octreotide acetate solution for injection • octreotide sustained release (MTD201)
4years
Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO 2020)
MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
Clinical • PK/PD data • Late-breaking abstract
|
IGF1 (Insulin-like growth factor 1)
|
Octreosphere (octreotide extended release) • adecatumumab (MT201) • octreotide acetate • octreotide sustained release (MTD201)
Share via
